MPN 2021 | Driver mutations in MPNs
Mary Frances McMullin
• 25 Oct 2021
Mary Frances McMullin, MD, Queens University Belfast, Belfast, UK, outlines the main driver mutations in myeloproliferative neoplasms (MPNs). Almost 95% of patients with polycythemia vera harbour a single point mutation in JAK2, JAK2 V167F, and a small portion carries JAK2 exon 12 mutations or other JAK2 mutations. In contrast, only 50% of patients with essential thrombocythemia carry the JAK2 V167 mutations and the other half harbour mutations in MPL and CALR, similarly to patients with myelofibrosis. Triple-negative patients carry other currently unknown driver mutations. This interview took place at the 2021 International Congress on MPNs congress in New York, NY.
